FDA Determines Regulatory Review Period for GENESIS NEUROSTIMULATION SYSTEM Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially approved the regulatory review period for the patent extension of the GENESIS NEUROSTIMULATION SYSTEM, a medical device, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.